3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
4
Neoplasms
3
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
137
Nivolumab
116
Ipilimumab
68
Cyclophosphamide
33
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
binimetinib
22
fludarabine
21
Interleukin-2
20
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
CTLA-4 Antigen
16
cemiplimab
15
atezolizumab
15
aldesleukin
15
Radiosurgery
15
fludarabine phosphate
14
Opdualag
14
Radiotherapy
11
lenvatinib
10
Blood Specimen Collection
10
lifileucel
9
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
spartalizumab
7
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
entrectinib
×
1 year
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled